 |
Designer Vaccine - Hope of The Future |
 |
Home Site Map This Site Is For Sale |
Dynavax Enters Into Supply and Option Agreement for Development of Universal Influenza Vaccine : Novartis Will Contribute Trivalent Vaccine to the C
Cool Websites WeeklyWhen you sign-up for Cool Websites Weekly free membership you will get a free and new Cool Website each week for as long as you remain a free Cool Websites Weekly member. For a limited time when you sign-up for a Cool Websites Weekly free membership, as a bonus you will receive a free link to get free software daily at no cost. This bonus link will appear on your first Cool Website Weekly email after you have verified that you have sign-up for your free Cool Websites Weekly membership. IMPORTANT: Unless you complete the verification process, you will not receive your free membership or bonus link to free daily software - please check you email for verification information. We require this verification process in order to make sure that you requested the free membership and not someone else. Please remember that if you are dissatisfied at any time with your Cool Websites Weekly free membership, you may cancel at anytime and not receive any more Cool Websites Weekly e-mails.
Get Breaking News Video From Msnbc.
BERKELEY, Calif. (Business Wire EON) July 23, 2008 -- "This agreement with one of the world's leading manufacturers and innovators in influenza vaccines is a fundamental step for the successful development of our universal flu vaccine," said Dino Dina, chief executive officer and president of Dynavax. "With this agreement in place we can proceed toward the clinic and to licensure through a known regulatory pathway."
Under the agreement Dynavax will conduct early-stage development through a defined proof-of-concept. If Novartis exercises the right to negotiate a further agreement for development and commercialization, Dynavax would retain co-commercialization rights in the U.S. and receive product royalties outside of the U.S. Should the option not be exercised, Novartis remains committed to providing commercial supply of trivalent influenza vaccine with pre-agreed commercial terms and Dynavax retains the right to independently continue with late-stage development and commercialization.
The Dynavax Universal Influenza Vaccine combines a proprietary second-generation TLR9 agonist with two conserved influenza antigens, nucleoprotein (NP) and the extracellular domain of matrix protein 2 (M2e), and a trivalent influenza vaccine. The Dynavax vaccine is designed to be differentiated from other influenza vaccines by providing both an adjuvant effect to enhance the immunogenicity of the seasonal vaccine and cross-strain protection via conserved influenza antigens.
Gary Van Nest, Vice President of Vaccines stated, "We have demonstrated that our novel vaccine can provide cross-strain protective immunity in pre-clinical challenge models and that NP-ISS induces strong type-1 helper T cell (Th1) and cytotoxic T cell responses (CTL) that kill virus infected cells. M2e-ISS induces cytotoxic antibody responses that also kill infected cells, limiting disease severity. In effect, even if a standard flu vaccine does not match the virus that circulates in the season, our universal flu vaccine can potentially protect against viral disease caused by strains not included in the standard vaccine."
About Influenza
Influenza is a contagious respiratory illness caused by influenza viruses that can mutate frequently. Serious illness and death from influenza are highest among persons >65 years of age and children <2 years of age. Annual epidemics are estimated to result in 3-5 million severe illnesses and 250,000-500,000 deaths worldwide.
Vaccination is the most effective tool for preventing influenza but is currently limited by vaccines that do not provide adequate protection against mutated virus strains or in the populations with the greatest disease burden. In fact, during the 2007-2008 flu season, 2 of the 3 flu strains in the vaccine were mis-matched vs. circulating strains, substantially hampering the efficacy of the vaccine. Novel vaccines that can address these limitations are needed.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergy, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our clinical product candidates include: HEPLISAV?, a hepatitis B vaccine partnered with Merck & Co., Inc.; a therapy for metastatic colorectal cancer; and therapies for hepatitis B and C. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH partially funds our preclinical work on a universal vaccine for influenza. Symphony Dynamo Inc. (SDI) funds our colorectal cancer and hepatitis C therapeutic programs. While NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.
Dynavax Forward-looking Statement
This press release contains forward-looking statements that are subject to a number of risks and uncertainties, including statements about the potential for an extended collaboration beyond the current arrangement with Novartis, committed supply of trivalent influenza vaccine for our universal influenza vaccine product candidate, initiation and timing of clinical trials and the regulatory pathway for our vaccine product candidate and the expected features of the vaccine. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including difficulties or delays in development, initiation and completion of clinical trials, the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process; achieving our Merck collaborative agreement objectives, resuming development and obtaining regulatory approval for HEPLISAV; continuation of our third party collaboration and funding arrangements; the scope and validity of patent protection and the possibility of claims against us based on the patent rights of others; our ability to obtain additional financing to support our operations; and other risks detailed in the "Risk Factors" section of our Quarterly Report on Form 10-Q. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
This press release has been reprinted from PRWEB per the terms and conditions of the copyright notice.
Resources of Interest Exploring Things Career Job Work Exploring The News Opportunity Explorer US Junior Golf Blog Exploring Discount Coupons Surprise Websites Video Utube Clip Domain Name Registration Lookup BuyIBusiness Holiday Exploring PCs MACs Game Improvement Clubs Exploring Football Sports Exploring Exploring Cars 2ndHandProducts Auction Exploring Exploring Financial Aid Exploring Scholarships Exploring Grants Domains With Value Army Recruiter Air Force Recruiter Coast Guard Recruiter Guard Recruiter Marine Recruiter Reserve Recruiter Navy Recruiter Explore Work At Home Explore Sightseeing In America Exploring Credit Cards StarrTrack Exploring Comic Books Explore Kitchen Remodeling Vol Army Domain Name Real Estate Lowest Interest Card Airport Lobby US Golf News US Junior Golf News Veteran's Benefits Alaska Exploring Exploring NASCAR Explore The Military Exploring Mesothelioma US Tennis News Utube Clip Body Charm Exploring Hair Styles Wall Street Country Coaled US Baseball News Immigration Island Flowers For You Star Track Domains Art Exploring Business Lister Global Climate News Explore The Law My School Stuff Run For The White House Real Estate Exploring Holy Land War Clip Utube Video Volunteer Army 1EZ Business 1EZ Domain My School Stuff Your Vacation Mountain Lakes 9-1-1 Airport Lobby Info Airport Lobby - Flight Business Army Strong - A Strong Army Is Essential Army Strong - Yes We Need A Strong Army Army Stronge - News And Information Be Master Of Your Domain - Domain Master Billion Nuggets - Gold Rush Business Listers Carbon Footprints - News Briefs Civilian Reserve Corps - Alternatives Cludder Co-Authored Company Lobby Depo Designer Vaccine - Hope Of The Future Designer Vaccines - Drugs Of The Future Discoverer -Exploring Science Domain Renewal Exploring Physical Therapy Exploring Talk Radio Flowers For You - On Your Cell Phone Fresh Air And Clean Water- Information Guard Recruiters - Search Lady Vols Guard Recruiters - Military Careers InstaPundit - News To View On The Run Internet Domain Registrations King James Bible Lowest Interest Cash Advance Lowest Interest Mortgage Rate Motel Lobby My School Stuff - Search My School Stuff - Reviews Retirement Exploring Rocky Top Sheriff Report Talk With A Geek The Class Of 67 US Golf News - For Tour Professionals Utube Clip - News And Info Virtual Domain Real Estate War Craft World Web Register Japan Exploring Chinese Exploring Exploring Golf Shopping Golfer Dubai Exploring America Exploring WBIR - Web Based Information Research Exploring Gas And Oil Prices Exploring Recipes Exploring UFO's Exploring Country Music Volunteer Military Instant News Exploring Weddings Exploring High School Musicals Exploring Cars Exploring Weight Loss Exploring Gatlinburg Mexico Exploring Business Exploring I Apology User Graphics 4U Exploring Pigeon Forge Exploring College MicroFueler BuyUTek Mars Exploring Carpet-Central Get Teed Off Exploring The Olympics Privacy Policy For This WebSite
|
|
||||||||||||||||
